We are looking for partnering opportunities on new assets (small molecules, biologics, or advanced therapies) in clinical or preclinical development stages that could be used for the treatment of dermatological conditions.
Preferably, the assets should target immuno-inflammatory pathways with rationale for dermatological indications, such as atopic dermatitis, hidradenitis suppurativa, alopecia areata, and vitiligo, or be suitable for non-melanoma skin cancer, or rare dermatological indications.
Our interest
New assets in clinical or preclinical development stages
